Nasdaq:HRTX
HERON THERAPEUTICS, INC. /DE/
A clinical-stage biopharmaceutical firm advancing innovative treatments for neurological conditions with a focus on CNS disorders.
Key Metrics
Investment Thesis
Bull Case
Investors might buy this stock based on the company's growing revenue trajectory and strong pipeline potential in the lucrative neurological disorder market. The ability to secure financing through share issuances ($18.3M) demonstrates access to capital markets necessary to sustain development until commercial milestones are reached. If key clinical trials succeed, the first-mover advantage in novel CNS therapies could lead to a significant valuation re-rating.
Bear Case
The stock carries high risk due to persistent net losses and a large retained earnings deficit that signals ongoing financial stress without consistent profitability. Revenue growth has not yet translated into operational efficiency, as evidenced by negative cash flow from operations and high non-cash adjustments impacting the bottom line. Investors may avoid the stock given the reliance on continuous equity raises to cover operating deficits in a competitive pharmaceutical landscape.
About HERON THERAPEUTICS, INC. /DE/
Heron Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological disorders, primarily within the central nervous system markets. The company's recent financials reflect significant investments in research and development alongside substantial marketing expenses to drive commercialization efforts. Key revenue streams currently stem from product sales and partnerships aimed at addressing unmet needs in neurology.
Analysis
Management Discussion
Recent financial performance shows revenue growth to $154.9M from 2022 levels, yet operating profit remains negative at -$2.5M driven by elevated general and administrative and marketing expenses. Cash flow from operations was -$27.6M, indicating the company continues to burn cash to fund its research pipeline and commercial expansion before achieving positive cash conversion. The balance sheet shows healthy current assets of $238.1M against current liabilities of $96.1M, providing a cushion for ongoing operational needs.
Industry Overview
The biopharmaceutical industry for neurological disorders is characterized by high R&D costs, long development timelines, and significant regulatory hurdles before product launch. Companies in this space typically operate with negative earnings initially, relying on external funding to bridge the gap between clinical trials and market approval. Market dynamics favor firms with differentiated science and strong commercial partnerships to navigate the complex pathway of CNS drug approvals.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $107.7M | $127.0M | $144.3M | $154.9M |
| Cost of Revenue | $54.9M | $65.1M | $38.6M | $41.3M |
| Gross Profit | $52.8M | $61.9M | $105.6M | $113.6M |
| Operating Expenses | $227.5M | $172.6M | $117.2M | $116.1M |
| Operating Income | $-174.7M | $-110.6M | $-11.5M | $-2.5M |
| R&D | $107.5M | $55.9M | $16.7M | $12.4M |
| G&A | $37.4M | $49.0M | $53.4M | $54.6M |
| Marketing | $82.5M | $67.6M | $47.1M | $49.1M |
| Stock-Based Comp | $43.0M | $32.9M | $13.0M | $10.3M |
| D&A | $2.9M | $2.9M | $2.5M | $2.3M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2.5M | $3.9M | — | — |
| Interest Income | $1.6M | $3.4M | $3.5M | $1.9M |
| Pre-Tax Income | $-174.7M | $-110.6M | $-11.5M | $-2.5M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-174.7M | $-110.6M | $-11.5M | $-2.5M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-182.0M | $-110.6M | $-13.6M | $-20.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-182.0M | $-110.6M | $-13.6M | $-20.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $205.4M | $188.8M | $209.0M | $238.1M |
| Cash & Equivalents | $15.4M | $28.7M | $25.8M | $28.6M |
| Accounts Receivable | $52.0M | $60.1M | $78.9M | $89.6M |
| Inventory | $54.6M | $42.1M | $53.2M | $92.7M |
| Prepaid Expenses | $14.0M | $6.1M | $17.7M | $9.1M |
| Other Current Assets | $69.5M | $51.7M | $33.5M | $18.0M |
| Long-Term Assets | $45.5M | $33.7M | $24.1M | $17.8M |
| PP&E (Net) | $22.2M | $20.2M | $14.9M | $12.4M |
| Operating Leases | $7.6M | $5.4M | $2.8M | $0 |
| Other LT Assets | $15.7M | $8.1M | $6.5M | $5.4M |
| Total Assets | $251.0M | $222.5M | $233.1M | $255.9M |
| Current Liabilities | $82.4M | $79.7M | $91.5M | $96.1M |
| Accounts Payable | $3.2M | $3.2M | $11.7M | $9.0M |
| Current Leases | $2.7M | $3.1M | $3.0M | $0 |
| Other Current Liab | $76.4M | $73.4M | $76.7M | $87.1M |
| Long-Term Liabilities | $155.0M | $176.8M | $175.3M | $145.4M |
| LT Operating Leases | $5.5M | $2.8M | — | — |
| Other LT Liab | $149.5M | $174.0M | — | — |
| Total Liabilities | $237.4M | $256.5M | $266.8M | $241.5M |
| Shareholders' Equity | $13.6M | $-34.0M | $-33.7M | $14.3M |
| Paid-In Capital | $1.81B | $1.87B | $1.88B | $1.95B |
| Retained Earnings | $-1.80B | $-1.91B | $-1.92B | $-1.94B |
| AOCI | $-19.0K | $13.0K | $13.0K | $4.0K |
| Total L&E | $251.0M | $222.5M | $233.1M | $255.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-182.0M | $-110.6M | $-13.6M | $-20.2M |
| Non-Cash Adjustments | $2.9M | $72.4M | $-57.6M | $-55.9M |
| Working Capital Changes | $32.2M | $-20.6M | $48.6M | $48.5M |
| Cash from Operations | $-146.9M | $-58.8M | $-22.5M | $-27.6M |
| Capital Expenditures | $1.8M | $1.5M | $1.7M | $317.0K |
| Cash from Investing | $-3.3M | $18.0M | $18.7M | $16.0M |
| Cash from Financing | $75.1M | $54.1M | $940.0K | $14.4M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-75.2M | $13.3M | $-2.9M | $2.8M |
| Beginning Cash | $90.5M | $15.4M | $28.7M | $25.8M |
| Ending Cash | $15.4M | $28.7M | $25.8M | $28.6M |
Frequently Asked Questions
How does HERON THERAPEUTICS, INC. /DE/ make money?
The company operates through core therapeutic areas targeting neurological diseases, supported by commercialization efforts that have generated $154.9M in revenue for the latest year. Financial data indicates heavy allocation to general and administrative expenses ($54.6M) and marketing costs ($49.1M), suggesting a segment structure reliant on high-touch sales models typical of specialty neurology.
What are the main risks for HRTX?
The company faces substantial operating losses, with net profit at -$20.2M, raising concerns about long-term burn rates and ability to reach profitability. High accounts receivable ($89.6M) relative to cash on hand suggests potential collection risks or working capital inefficiencies in a pre-commercial phase. Dependence on equity financing is evident given the retained earnings deficit of -$1.94B, which could dilute shareholders if cash reserves deplete. Regulatory approval timelines for novel neurological therapies remain uncertain and impact future revenue recognition.
What is HRTX's competitive advantage?
The company leverages proprietary intellectual property in neurological therapeutics to differentiate its pipeline from competitors. Strong cash flow from financing activities ($14.4M) and share issuances ($18.3M) provide liquidity to sustain R&D programs despite current losses. Strategic focus on high-value CNS disorders offers a potential for significant market penetration upon successful product approvals.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.